Interim Report EURAP International May 2014 

BACKGROUND
All old-generation antiepileptic drugs (AEDs) are considered to be teratogenic and AEDs are among the most common causes of adverse effects to the foetus. The risks associated with the treatment of epilepsy during pregnancy is therefore of major concern to all women of childbearing potential with epilepsy. The information on the comparative teratogenicity of these AEDs in humans is, however, conflicting, mainly due to inadequate sample size and methodological differences between previous studies. The teratogenic potential of newer AEDs is even less known, a situation that prevents a rational approach to AED treatment in women of childbearing potential.
To address this problem, it is necessary to compile more information on outcome of pregnancies following maternal exposure to AEDs. Such information is needed to provide pre-pregnancy counselling concerning teratogenic risks, and possibilities for specific prenatal monitoring, including prenatal diagnosis of foetal disorders associated with specific medications. Given the current number of available AEDs and combinations, very large numbers of pregnancies have to be evaluated in order to establish the safety of each regimen. Large denominators are also needed because of the qualitative diversity of the main endpoint of outcome, major congenital malformations.
A number of independent groups with experience and interest in maternal and foetal well-being in association with maternal AED use have agreed on a prospective international multi-centre study of pregnancies with AEDs. Data from all participating groups are shared in a Central Registry of Antiepileptic Drugs and Pregnancy (EURAP). EURAP was established in the first centres in some European countries and
has since then gradually expanded to include more centres and countries now involving also Asia, Oceania, Latin America and Africa. .....more  /DGfE/EURAP/Eurap-Studie/Grafiken/PDF 601 KB


More International Report Nov 2013

Central Study Coordinator
Dr. Dina Battino
Fondazione I.R.C.C.S
Neurological Institute Carlo Besta
Via Celoria 11
20 133 Milano, Italy
Tel: + 39 (0)2 23 94 2230
Fax: + 39 (0)2 700 42 91 60
E-mail: dbattino@istituto-besta.it

Chairman Central Project Commission
Dr. Torbjörn Tomson
Department of Neurology
Karolinska University Hospital
S-171 76 Stockholm
Sweden Tel: + 46 (0)8 51773705
Fax: + 46 (0)8 51773757
E-mail: torbjorn.tomson@karolinska.se  

infobox_top

/Seifenblase2.jpg

Ein gesundes neues Jahr 2018

Newsletter